Skip to main content
    M

    MDxHealth SA (MDXH)

    Official site

    HEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ

    $0.15
    +0.00 (+3.40%)

    Market Cap: $13.75M

    Last updated: Nov 17, 2026 at 11:03 AM ET

    MDxHealth SA (MDXH) Earnings: Report Dates and Results

    Updated Nov 12, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    In the quarter ended Sep 30, 2026, MDxHealth SA reported EPS of -$0.16, below the -$0.07 estimate. It beat the EPS estimate in 1 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    22%(5/23)
    Avg Surprise
    -57.02%

    Upcoming Estimates

    Report date not yet scheduledPeriod ending Dec 31, 2026
    EPS Consensus-$0.09
    Range-$0.11 - -$0.07
    7 analysts
    Revenue Consensus
    $26.38M
    Range$22.05M - $32.66M
    7 analysts

    Next Report

    MDXH's report for the quarter ending Dec 31, 2026 is not on the earnings calendar yet.

    MDXH Earnings Call

    The latest MDXH earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 23 quarters below that had an estimate, MDXH beat 5 and missed 18. The widest gap in the table came in the quarter ended Sep 30, 2021, when EPS landed 650.00% below the estimate.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.16-$0.07-$0.11 - -$0.06-128.57%MissN/A55 up, 0 downNov 12, 2026N/A
    Jun 30, 2026-$0.18-$0.12N/A-50.00%MissN/A50 up, 4 downAug 13, 2026$27.21M
    Mar 31, 2026-$0.17-$0.15-$0.20 - -$0.11-13.33%MissN/A51 up, 2 downMay 13, 2026$54.66M
    Dec 31, 2025-$0.17-$0.13-$0.14 - -$0.12-30.77%MissN/A50 up, 3 downFeb 26, 2026$54.66M
    Sep 30, 2025-$0.16-$0.11-$0.13 - -$0.11-45.45%MissN/A40 up, 1 downNov 12, 2025$27.43M
    Jun 30, 2025-$0.14-$0.12N/A-16.67%MissN/AN/A0 up, 0 downAug 14, 2025$26.61M
    Mar 31, 2025-$0.19-$0.13N/A-46.15%MissN/AN/A0 up, 0 downMay 14, 2025$24.29M
    Dec 31, 2024-$0.14-$0.19N/A+26.32%BeatN/AN/A0 up, 0 downFeb 26, 2025$48.06M
    Sep 30, 2024-$0.40-$0.25-$0.30 - -$0.25-60.00%MissN/A50 up, 0 downNov 6, 2024$23.32M
    Jun 30, 2024-$0.31-$0.26-$0.29 - -$0.23-19.23%MissN/A40 up, 0 downAug 21, 2024$41.99M
    Mar 31, 2024-$0.31-$0.30-$0.35 - -$0.27-3.33%MissN/A40 up, 0 downMay 1, 2024$19.83M
    Dec 31, 2023-$0.39-$0.25-$0.28 - -$0.02-56.00%MissN/A30 up, 0 downMar 6, 2024$38.75M
    Sep 30, 2023-$0.40-$0.19-$0.40 - -$0.02-110.53%MissN/A52 up, 0 downNov 7, 2023$19.35M
    Jun 30, 2023-$0.30-$0.22-$0.39 - -$0.03-36.36%MissN/A50 up, 0 downAug 23, 2023$31.45M
    Mar 31, 2023-$0.50-$0.40-$0.53 - -$0.04-25.00%MissN/A40 up, 0 downMay 15, 2023$14.70M
    Dec 31, 2022-$1.10-$0.65-$0.85 - -$0.53-69.23%MissN/A31 up, 0 downMar 9, 2023$24.05M
    Sep 30, 2022-$0.50-$0.53-$0.54 - -$0.48+5.66%BeatN/A31 up, 1 downOct 27, 2022$11.15M
    Jun 30, 2022-$0.70-$0.60N/A-16.67%MissN/AN/AN/AAug 25, 2022$13.01M
    Mar 31, 2022-$0.50-$0.53-$0.59 - -$0.53+5.66%BeatN/A30 up, 0 downApr 27, 2022$6.11M
    Dec 31, 2021-$0.88-$0.47N/A-87.23%MissN/AN/A0 up, 0 downMar 2, 2022$11.51M
    Sep 30, 2021-$4.50-$0.60N/A-650.00%MissN/AN/AN/ANov 5, 2021$5.50M
    Mar 31, 2021-$0.06N/AN/AN/AN/AN/AN/AN/AJun 30, 2021$5.06M
    Dec 31, 2020-$0.06N/AN/AN/AN/AN/AN/AN/AMar 3, 2021$8.58M
    Sep 30, 2020-$0.08N/AN/AN/AN/AN/AN/AN/ADec 31, 2020$4.29M
    Jun 30, 2020-$0.60-$1.60N/A+62.50%BeatN/AN/AN/ASep 29, 2020$9.88M
    Mar 31, 2020-$0.09N/AN/AN/AN/AN/AN/AN/AJun 30, 2020$4.94M
    Dec 31, 2019-$0.09N/AN/AN/AN/AN/AN/AN/AMar 31, 2020$912000
    Sep 30, 2019-$0.22N/AN/AN/AN/AN/AN/AN/ADec 31, 2019$456000
    Jun 30, 2019-$0.22N/AN/AN/AN/AN/AN/AN/ASep 30, 2019$10.87M
    Mar 31, 2019-$0.12N/AN/AN/AN/AN/AN/AN/AJun 30, 2019$5.44M
    Dec 31, 2018-$0.12N/AN/AN/AN/AN/AN/AN/AMar 31, 2019$11.20M
    Sep 30, 2018-$0.15N/AN/AN/AN/AN/AN/AN/ADec 31, 2018$5.60M
    Jun 30, 2018-$0.80-$1.70N/A+52.94%BeatN/AN/AN/AAug 30, 2018$17.20M
    Mar 31, 2018-$0.14N/AN/AN/AN/A-2800.0%N/AN/AJun 30, 2018$8.60M
    Dec 31, 2017-$0.14N/AN/AN/AN/A-2800.0%N/AN/AMar 31, 2018$16.25M
    Sep 30, 2017-$0.13N/AN/AN/AN/AN/AN/AN/ADec 31, 2017$8.12M
    Jun 30, 2017-$0.13N/AN/AN/AN/AN/AN/AN/ASep 30, 2017$24.26M
    Mar 31, 2017$0.01N/AN/AN/AN/AN/AN/AN/AJun 30, 2017$12.13M
    Dec 31, 2016$0.01N/AN/AN/AN/AN/AN/AN/AMar 31, 2017$17.02M
    Sep 30, 2016-$0.06N/AN/AN/AN/AN/AN/AN/ADec 31, 2016$8.51M
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$0.66, after -$1.16 the year before. It was -$0.20 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$0.66N/A
    Dec 31, 2024-$1.16N/A
    Dec 31, 2023-$1.59N/A
    Dec 31, 2022-$2.80N/A
    Dec 31, 2021-$5.44N/A
    Dec 31, 2020-$0.83N/A
    Dec 31, 2019-$0.65N/A
    Dec 31, 2018-$1.20N/A
    Dec 31, 2017-$0.39N/A
    Dec 31, 2016-$0.20N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 4,400 words across 8 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20264,4188
    2026Q2Jun 30, 20264,2859
    2026Q1Mar 31, 20263,9137
    2025Q4Dec 31, 20253,7297
    2025Q3Sep 30, 20256,1019
    2025Q1Mar 31, 20256,33710
    2024Q4Dec 31, 20244,15910
    2024Q3Sep 30, 20244,5338

    2026Q3 Earnings Call

    Opening remarks

    John Fraunces Moderator Before we begin, I would like to remind everyone that the company will make forward-looking statements during today's call. Whether in prepared remarks or during the Q&A session, these forward-looking statements are subject to inherent risks and uncertainties. These risks and uncertainties are detailed in the risk factors section of the company's filings with the Securities and Exchange Commission, specifically in the company's annual report on Form 20-F. I will now turn the call over to Michael McGarrity, Chief Executive Officer.

    Michael McGarrity CEO Thanks, John. Thank you all for joining us for our third quarter 2026 earnings conference call. With me today is Ron Kalfus, Interim Chief Financial Officer. Since I joined MDxHealth, we have been consistent in our commitment to transparency, operating discipline, and our core principles of focus, execution, and growth. While our third quarter results fell short of our expectations, that commitment remains unchanged. Simply put, our Q3 results reflected temporary disruption in our commercial execution, driven by accelerated turnover within our sales organization following the discontinuation of Resolve, which was catalyzed by aggressive targeting from outside recruiters. While our disciplined commercial process has served as the foundation of our forecast accuracy and consistent performance over the past four years, that process was clearly disrupted by this recent impact on our sales force. Importantly, we do not believe these factors represent a change in the credibility and reputation we have built with our customer base, the underlying clinical demand for our products, or our long-term market opportunity. However, as I have noted before, you are defined not by what happens to you, but by how you respond. In direct response to this challenge, we have initiated a comprehensive restructuring of our commercial organization designed to reset our focus and process across our sales, marketing, and client services groups. As part of this reorganization, we have eliminated the Chief Commercial Officer role and have effectively split our sales and marketing functions into two distinct operating groups, both of which will report directly to me. Splitting our sales and marketing groups provides clear delineation and direct accountability for product strategy and sales execution, while simultaneously enhancing the overall customer experience. Based on my prior experience operating under this exact model, separating these functions establishes a vital check and balance on what had become a vertical operating structure, giving direct visibility into both territory-level execution and commercial strategy. Over the past several weeks, we have made considerable progress in backfilling and rebuilding our sales team, and we are highly encouraged by the caliber of talent and industry experience we are attracting to MDxHealth. Selection, development, and retention are the foundational pillars of our process through this commercial reset.

    Frequently Asked Questions About MDXH

    Did MDXH beat earnings estimates last quarter?

    No. MDxHealth SA reported EPS of -$0.16 for the quarter ended Sep 30, 2026, below the -$0.07 estimate by 128.57%.

    What EPS do analysts expect from MDXH next quarter?

    The consensus EPS estimate for MDxHealth SA for the quarter ending Dec 31, 2026 is -$0.09 from 7 analysts, with estimates from -$0.11 to -$0.07.

    How often does MDXH beat earnings estimates?

    MDxHealth SA beat the EPS estimate in 1 of the last 8 quarters, with an average surprise of -38.08%.